Tenofovir disoproxil fumarate

Drug Profile

Tenofovir disoproxil fumarate

Alternative Names: Bis-POC-PMPA; GSK548470; PMPA-oral; Tenofovir DF; Tenozet; Viread

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Institute of Organic Chemistry and Biochemistry (Prague); Rega Institute for Medical Research
  • Developer Gilead Sciences; GlaxoSmithKline
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; HIV infections

Most Recent Events

  • 28 Jan 2016 Gilead completes a phase III trial in Hepatitis B in USA, Australia, Bulgaria, Canada, Czech Republic, France, Germany, Greece, Italy, the Netherlands, New Zealand, Poland, Spain, Turkey and United Kingdom (NCT00116805)
  • 01 Jan 2016 Gilead Sciences completes a phase III trial in Hepatitis B in USA, United Kingdom, Australia, Canada, Czech Republic, France, Germany, Italy, New Zealand, Poland, Spain, Turkey and in the Netherlands (NCT00117676)
  • 01 Dec 2015 Gilead Sciences completes a phase III trial for Hepatitis B (in adolescents) in Belgium, Bulgaria, France, Germany, Poland, Romania, Spain, Turkey, USA and United Kingdom (NCT00734162/ EudraCT2007-003704-35)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top